Tags

Type your tag names separated by a space and hit enter

Rotavirus vaccine (RotaTeq).
Paediatr Drugs. 2006; 8(3):197-202; discussion 203-4.PD

Abstract

RotaTeq is a live, oral, pentavalent human-bovine reassortant rotavirus vaccine approved for use in the prevention of G1-G4 rotavirus gastroenteritis in infants and children. Rotavirus vaccine demonstrated good immunogenicity in healthy infants. Three oral doses of rotavirus vaccine had a protective efficacy against G1-G4 rotavirus gastroenteritis of any severity of 74%, and a protective efficacy against severe G1-G4 rotavirus gastroenteritis of 98%, in the randomized, double-blind, placebo-controlled, multicenter REST (Rotavirus Efficacy and Safety Trial) study; the per-protocol efficacy analysis included >4500 infants. Healthcare resource use was reduced by rotavirus vaccine, with a 94.5% reduction in the incidence of hospitalization or emergency department care because of G1-G4 rotavirus gastroenteritis. This analysis of the REST trial included >57,000 infants. Rotavirus vaccine did not increase the risk of intussusception within 42 days of any dose, according to an analysis of the REST trial including almost 70,000 infants. Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group.

Authors+Show Affiliations

Adis International Inc., Yardley, PA 19067, USA. demail@adis.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16774301

Citation

Keating, Gillian M.. "Rotavirus Vaccine (RotaTeq)." Paediatric Drugs, vol. 8, no. 3, 2006, pp. 197-202; discussion 203-4.
Keating GM. Rotavirus vaccine (RotaTeq). Paediatr Drugs. 2006;8(3):197-202; discussion 203-4.
Keating, G. M. (2006). Rotavirus vaccine (RotaTeq). Paediatric Drugs, 8(3), 197-202; discussion 203-4.
Keating GM. Rotavirus Vaccine (RotaTeq). Paediatr Drugs. 2006;8(3):197-202; discussion 203-4. PubMed PMID: 16774301.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rotavirus vaccine (RotaTeq). A1 - Keating,Gillian M, PY - 2006/6/16/pubmed PY - 2007/1/17/medline PY - 2006/6/16/entrez SP - 197-202; discussion 203-4 JF - Paediatric drugs JO - Paediatr Drugs VL - 8 IS - 3 N2 - RotaTeq is a live, oral, pentavalent human-bovine reassortant rotavirus vaccine approved for use in the prevention of G1-G4 rotavirus gastroenteritis in infants and children. Rotavirus vaccine demonstrated good immunogenicity in healthy infants. Three oral doses of rotavirus vaccine had a protective efficacy against G1-G4 rotavirus gastroenteritis of any severity of 74%, and a protective efficacy against severe G1-G4 rotavirus gastroenteritis of 98%, in the randomized, double-blind, placebo-controlled, multicenter REST (Rotavirus Efficacy and Safety Trial) study; the per-protocol efficacy analysis included >4500 infants. Healthcare resource use was reduced by rotavirus vaccine, with a 94.5% reduction in the incidence of hospitalization or emergency department care because of G1-G4 rotavirus gastroenteritis. This analysis of the REST trial included >57,000 infants. Rotavirus vaccine did not increase the risk of intussusception within 42 days of any dose, according to an analysis of the REST trial including almost 70,000 infants. Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group. SN - 1174-5878 UR - https://www.unboundmedicine.com/medline/citation/16774301/Rotavirus_vaccine__RotaTeq__ L2 - https://dx.doi.org/10.2165/00148581-200608030-00008 DB - PRIME DP - Unbound Medicine ER -